Policy Focus On Drug Cost-Effectiveness Studies Could Take Heat Off Devices
This article was originally published in The Gray Sheet
Executive Summary
Medical devices may enjoy a temporary reprieve from policymakers' increasing calls for rigorous cost-effectiveness analyses, with the current spotlight directed on pharmaceuticals
You may also be interested in...
Carotid Artery Disease Screening Should Make AHRQ Research List – Guidant
Guidant is requesting the Agency for Healthcare Research & Quality to assign the study of female cardiovascular care quality to a list of CMS research priorities to be generated under the Medicare Modernization Act
AdvaMed Issues National Coverage Evidentiary Standards Policy Statement
AdvaMed plans to disseminate its 1national coverage evidence standards policy statement to Capitol Hill staffers and CMS officials
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.